FDA Approves Veligrotug for All Stages of Thyroid Eye Disease
A new monoclonal antibody drug shows significant eye bulging reduction and double-vision relief for both active and chronic thyroid eye disease.
Summary
The FDA has approved veligrotug (Lumvoa) for thyroid eye disease (TED), a condition where the immune system attacks eye tissues, causing bulging eyes and double vision. Unlike its predecessor teprotumumab, veligrotug is the first treatment labeled for both the active and chronic forms of the disease. In clinical trials, patients saw eye protrusion shrink by nearly 3 mm on average compared to minimal change with placebo. More than half of patients with active disease achieved complete resolution of double vision. Administered via five intravenous infusions over 12 weeks, the drug works by blocking the IGF-1R receptor. Side effects include muscle spasms, headache, and hearing impairment. A subcutaneous version is currently in phase III trials.
Detailed Summary
Thyroid eye disease is an autoimmune condition most often linked to Graves' disease, where inflammation and tissue expansion behind the eyes causes proptosis (bulging) and diplopia (double vision). Left undertreated, it can significantly impair quality of life and even threaten vision. The FDA approval of veligrotug (Lumvoa) marks a meaningful step forward by offering effective treatment across the full disease spectrum.
Veligrotug is a humanized monoclonal antibody that fully blocks the insulin-like growth factor 1 receptor (IGF-1R), the same target as teprotumumab, which was previously the only non-surgical option. What distinguishes veligrotug is its FDA labeling for both active and chronic TED — a first for any approved therapy in this category.
Two phase III trials, THRIVE and THRIVE-2, supported the approval. In active disease patients, veligrotug reduced eye protrusion by an average of 2.89 mm versus 0.48 mm for placebo by week 15. In chronic disease patients, the reduction was 2.34 mm versus 0.46 mm. Complete resolution of double vision was achieved in 54% of active disease patients on veligrotug compared to 12% on placebo, and 32% versus 14% in chronic disease patients.
The drug carries no contraindications, though clinicians should monitor for infusion reactions, inflammatory bowel disease, hyperglycemia, and hearing impairment. Common side effects include muscle spasms, headache, fatigue, and diarrhea. The treatment course is five infusions given every three weeks over 12 weeks.
For health-conscious readers, this approval is relevant as thyroid autoimmunity is common, particularly in women, and often goes undertreated in its chronic phase. A second IGF-1R antibody, elegrobart, delivered via subcutaneous injection, is in phase III trials and may eventually offer a more convenient alternative.
Key Findings
- Veligrotug reduced eye protrusion by ~2.89 mm in active TED vs 0.48 mm with placebo by week 15.
- 54% of active TED patients achieved complete double-vision resolution versus 12% on placebo.
- First FDA-approved drug labeled for both active and chronic thyroid eye disease.
- Treatment involves five IV infusions over 12 weeks with no listed contraindications.
- A subcutaneous version (elegrobart) is currently in phase III trials, potentially offering easier delivery.
Methodology
This is a news report from MedPage Today summarizing an FDA drug approval announcement. Evidence is based on two phase III randomized controlled trials (THRIVE and THRIVE-2) that met primary and all secondary endpoints. Source credibility is high; MedPage Today is a peer-respected medical journalism outlet.
Study Limitations
The article is a brief news summary and does not include full trial data, long-term follow-up outcomes, or comparative efficacy against teprotumumab. Cost and insurance accessibility remain practical barriers. Readers should consult the primary clinical trial publications and FDA prescribing label for complete safety and efficacy details.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: